Research programme: matrix metalloproteinase inhibitors - Cengent Therapeutics/De Novo
Alternative Names: MMP inhibitors - Cengent Therapeutics/De NovoLatest Information Update: 31 Aug 2007
At a glance
- Originator Cengent Therapeutics; De Novo Pharmaceuticals
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 31 Aug 2007 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 31 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 31 Aug 2007 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)